Waton Financial 株価情報 (NASDAQ: WTF)

最新ニュース Waton Financial (NASDAQ:WTF) 株価情報

Waton Financial Ltd is a holding company that operates its business through subsidiaries in the securities brokerage and distribution services, margin financing services, and other ancillary services business; Software licensing and related support services, including licensing of trading platform applications, upgrades and enhancements, maintenance; and other associated services to securities brokers and financial institutions. The group also provided software licensing and related support services, including licensing trading platform applications, and others.

Waton Financial Limited - Ordinary Shares

Waton Financial Ltd

Wintrust Financial Corporation - Common Stock

Wintrust Financial Corp

Wintrust Financial Corporation - Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series D

Wintrust Financial Corporation - Depositary Shares, Each Representing a 1/1,000th Interest in a Share of 6.875% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $1.07 by 1.87 percent. This is a 11.22 percent increase over earnings of $0.98 per share from the same period last year. The company reported quarterly sales of $10.36 billion which missed the analyst consensus estimate of $10.40 billion by 0.39 percent. This is a 3.95 percent increase over sales of $9.96 billion the same period last year.

Earnings

News

Abbott Laboratories Q1 2025 Adj EPS $1.09 Beats $1.07 Estimate, Sales $10.36B Miss $10.40B Estimate

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and maintains $75 price target.

Price Target

Reiteration

Analyst Ratings

SRPT

HC Wainwright & Co. Reiterates Neutral on Sarepta Therapeutics, Maintains $75 Price Target

WIIM

RDHL

Redhill Biopharma shares are trading higher after the company announced the publication of an article titled 'Opaganib Promotes Weight Loss and Suppresses High-Fat Diet (HFD)-Induced Obesity and Glucose Intolerance' in the journal Diabetes, Metabolic Syndrome and Obesity.

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) with a Neutral and maintains $1 price target.

LYEL

HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target

ASML

AVGO

INTC

LRCX

Shares of chip stocks are trading lower after NVIDIA said it was recently informed by the US government that it will need a license to export chips to China.

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="586" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/15224016/Bear-1024x586.jpg" alt="" class="wp-image-10727" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/15224016/Bear-1024x586.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/15224016/Bear-300x172.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/15224016/Bear-768x440.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/15224016/Bear.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Fading The (Brief) Tariff Relief Rally</h2>
The ostensible reason why the market rallied on Monday was the news from Friday night that the Trump administration was exempting items such as laptops and smart phones from its latest round of "reciprocal" tariffs on China. We decided to fade that rally for a few tariff-related reasons:&nbsp;
<h3 class="wp-block-heading">The reciprocal tariffs still apply to 78% of U.S. imports from China </h3>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I would interpret the tariff exemptions primarily as an attempt to mitigate the impact on electronics and consumers more than as a signal of a US-China deal. The exempted categories cover about 22% of US imports from China. <a href="https://t.co/T4TdUKPl0d">https://t.co/T4TdUKPl0d</a> <a href="https://t.co/kNbgl7UGoO">pic.twitter.com/kNbgl7UGoO</a>
&mdash; Gerard DiPippo (@gdp1985) <a href="https://twitter.com/gdp1985/status/1911066108632719847?ref_src=twsrc%5Etfw">April 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">The 20% fentanyl-related tariffs from March still apply to all U.S. imports from China.</h3>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Washington Post: maybe your reporters should try reading before posting. These products are subject to the tariff under the original IEEPA on China of 20 percent. <a href="https://t.co/MI4oDEb8S3">https://t.co/MI4oDEb8S3</a>
&mdash; Stephen Miller (@StephenM) <a href="https://twitter.com/StephenM/status/1911092862076289243?ref_src=twsrc%5Etfw">April 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Within the next month or two, the U.S. may levy&nbsp;<a href="https://www.reuters.com/markets/us-commerce-secretary-says-exempted-electronic-products-come-under-separate-2025-04-13/">additional, new tariffs</a>&nbsp;on the electronics exempted from the reciprocal tariffs.&nbsp;</h3>
<h2 class="wp-block-heading">The Stocks We Bet Against&nbsp;</h2>
We decided to bet against three stocks on Monday. Below are their respective tariff vulnerabilities.&nbsp;
<h3 class="wp-block-heading">1. Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</h3>
Tariff Exposure:
<ul>
<li>20% Fentanyl-Related Tariff:&nbsp;Apple&#8217;s products, including iPhones, are subject to a 20% tariff imposed in response to China&#8217;s role in the fentanyl crisis. ​</li>
<li>Temporary Exemption from 125% Reciprocal Tariff:&nbsp;Apple&#8217;s products are currently exempt from the 125% reciprocal tariff on Chinese imports. ​<a href="https://www.reuters.com/markets/us-excludes-smartphones-computers-reciprocal-tariffs-2025-04-12/?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">Reuters</a></li>
</ul>
Future Risks:
<ul>
<li>The administration is considering new tariffs targeting semiconductors and the electronics supply chain, which could affect Apple products in the near future. ​<a href="https://nypost.com/2025/04/13/us-news/iphones-and-other-chinese-made-electronics-will-likely-be-subject-to-more-trump-tariffs-commerce-secretary-lutnik-says/?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">New York Post+1NPR+1</a></li>
</ul>
<h3 class="wp-block-heading">2. PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>)</h3>
Tariff Exposure:
<ul>
<li>20% Fentanyl-Related Tariff:&nbsp;PVH&#8217;s apparel and accessories imported from China are subject to this tariff (PVH is the parent company of the Calvin Klein and Tommy Hilfiger brands). ​</li>
<li>125% Reciprocal Tariff:&nbsp;Additionally, PVH faces a 125% reciprocal tariff on Chinese imports, bringing the total tariff rate to 145%. ​</li>
</ul>
Implications:
<ul>
<li>The combined tariffs significantly increase costs for PVH, potentially impacting profit margins and necessitating supply chain adjustments.</li>
</ul>
<h3 class="wp-block-heading">3. SolarEdge Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NYSE">SEDG</a>)</h3>
Tariff Exposure:
<ul>
<li>20% Fentanyl-Related Tariff:&nbsp;Applies to SolarEdge&#8217;s imports from China. ​</li>
<li>34% Reciprocal Tariff on Solar Equipment:&nbsp;SolarEdge&#8217;s solar equipment imports from China are subject to this tariff. ​</li>
<li>50% Section 301 Tariff:&nbsp;A 50% tariff applies to Chinese solar cells and modules, affecting SolarEdge&#8217;s products. ​</li>
</ul>
Implications:
<ul>
<li>The cumulative <a href="https://www.whitehouse.gov/fact-sheets/2025/02/fact-sheet-president-donald-j-trump-imposes-tariffs-on-imports-from-canada-mexico-and-china/?utm_source=chatgpt.com">tariffs </a>increase costs for SolarEdge, potentially affecting pricing strategies and competitiveness in the U.S. market.​</li>
</ul>
<h2 class="wp-block-heading">The Weakest Of Those Three Companies</h2>
Of those three companies, SolarEdge is clearly the weakest. Apple and PVH still look good on a fundamental basis (though the new tariffs aren&#8217;t priced in to most of their fundamental metrics yet). SolarEdge looks bad now, and will likely get worse given the new tariffs. Here are how each company compares on select Chartmill metrics: 
Apple:
<ul>
<li>Overall fundamental rating: 7</li>
<li>Profitability: 10</li>
<li>Growth: 5</li>
<li>Valuation 3</li>
</ul>
PVH:&nbsp;
<ul>
<li>Overall fundamental rating: 5</li>
<li>Profitability: 6</li>
<li>Growth: 4</li>
<li>Valuation 8</li>
</ul>
SolarEdge:
<ul>
<li>Overall fundamental rating: 2</li>
<li>Profitability: 1</li>
<li>Growth: 3</li>
<li>Valuation 1</li>
</ul>
For that reason, we placed an additional, longer-term bearish bet on SolarEdge.
<h2 class="wp-block-heading">Zigging When The Market Zags</h2>
There are a few newer companies that look like they&#8217;ll be dominant players for years. We&#8217;ll be looking to add long positions to them on the next leg down. And if we get another rally in the near term, we&#8217;ll be looking to add short positions on other companies facing tariff or other headwinds. If you&#8217;d like a heads up when we place our next trade, feel free to subscribe to our <a href="https://portfolioarmor.substack.com/p/trade-alert-betting-against-the-bounce">trading Substack</a>/occasional email list below.&nbsp;
And if want to just want to add downside protection on the next rally, as a reminder, you can&nbsp;download the Portfolio Armor optimal hedging app by aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone). Our app can help you find the least expensive hedges given your risk tolerance and time frame.
<figure class="wp-block-image size-full"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/15224936/QR-Code-3-2.jpg" alt="" class="wp-image-10728" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/trade-alert-betting-against-the-bounce"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/15231128/Widget-4-1.jpg" alt="" class="wp-image-10729" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/15231128/Widget-4-1.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/15231128/Widget-4-1-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Equities

Short Ideas

Technicals

Opinion

Markets

Trading Ideas

AAPL

SEDG

3 Stocks We Are Betting Against

UAL: 7% &#x7C; <a href="https://www.benzinga.com//node/44834729">United Airlines shares are trading higher after the company reported better-than-expected Q1 EPS results.</a>
&nbsp;
NVDA: -7% &#x7C; <a href="https://www.benzinga.com//node/44834645">NVIDIA shares are moving lower after the company said it was recently informed by the US government that it will need a license to export chips to China.</a>
&nbsp;
TSLA: -3% &#x7C; <a href="https://www.benzinga.com//node/44834716">Tesla shares are trading lower after reports indicating the company suspended its plans to ship parts from China for its Cybercab and Semi electric trucks.</a>

Movers

NVDA

TSLA

Market-Moving News for April 16th

Shares of airline stocks are trading higher in sympathy with United Airlines which reported a Q1 EPS beat.

United Airlines shares are trading higher after the company reported better-than-expected Q1 EPS results.

Tesla shares are trading lower after reports indicating the company suspended its plans to ship parts from China for its Cybercab and Semi electric trucks.

PERI

Perion Network Announced First Quarter Preliminary Revenue Of ~$88M (Vs. Cons. Of 83.7M), Adjusted EBITDA Of ~$1.5M And Adjusted EBITDA To Contribution Ex-tac Of ~4%

MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) on Wednesday released data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy,&nbsp;a type of nerve damage that can occur <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">in diabetes patients</a>.&nbsp;
In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low <a target="_blank" href="https://www.benzinga.com/exclusives" rel="noreferrer noopener">dose of Streptozotocin (STZ)</a>.
Treatment with Ketamir-2 led to a significant reduction in neuropathic pain symptoms, with some animals returning completely to pre-diabetic baseline sensitivity.
<ul>
<li>These results build upon prior preclinical studies using other neuropathy animal models, where orally administered Ketamir-2 outperformed FDA-approved neuropathic pain medications such as pregabalin and gabapentin, demonstrating a favorable safety profile.</li>
<li>Unlike traditional ketamine, Ketamir-2 does not induce dissociative or psychedelic effects and is not a substrate for P-glycoprotein, allowing for more efficient penetration across the blood-brain barrier.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44299076/exclusive-mira-pharmaceuticals-expands-pipeline-enhances-value-proposition-with-development-of-topical-formulation-for-lead-pain-treatment-candidate" rel="noreferrer noopener">EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate</a>
Diabetic neuropathy affects between 28% to 55% of patients with diabetes.
Current treatment options are limited, with first-line therapies such as pregabalin, gabapentin, and duloxetine often delivering only modest symptom relief. These drugs are frequently associated with side effects such as dizziness, fatigue, cognitive impairment, and gastrointestinal discomfort. Up to 50% of patients fail to achieve meaningful pain reduction.
At the same time, the demand for non-opioid therapies is growing rapidly, driven by the ongoing opioid crisis and heightened regulatory scrutiny. Ketamir-2's non-addictive profile and lack of dissociative side effects position it as a strong candidate in this emerging treatment landscape.
MIRA anticipates initiating its Phase 2a trial in diabetic neuropathy by the end of 2025, with the first human efficacy data expected in the first half of 2026.
In parallel, the company is developing a topical slow-release formulation of Ketamir-2 to provide localized pain relief with minimized systemic exposure.
In addition, MIRA is actively conducting ongoing studies assessing the efficacy of Ketamir-2 in models of post-traumatic stress disorder.
In March, MIRA Pharmaceuticals&nbsp;signed a binding letter of intent to acquire&nbsp;SKNY Pharmaceuticals, Inc.
The transaction includes a $5 million capital infusion of cash or equivalent consideration into MIRA, reinforcing its financial position and supporting the advancement of SKNY-1, a preclinical-stage oral drug candidate for weight <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44454746/exclusive-mira-pharmaceuticals-signs-to-acquire-skny-pharmaceuticals-expand-pipeline-into-weight-loss-and-smoking-cessation-drug" rel="noreferrer noopener">loss and smoking cessation</a>.
Price Action: MIRA stock closed at $0.89 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44828811/intel-growth-challenges-are-not-over-despite-altera-stake-sale-analyst" target="_blank" rel="noreferrer noopener">Intel Growth Challenges Are Not Over Despite Altera Stake Sale: Analyst</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

MIRA

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

NVIDIA shares are moving lower after the company said it was recently informed by the US government that it will need a license to export chips to China.

EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal'

EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Announces Results For Ketamir-2 In Diabetic Neuropathy Animal Model, Says Reinforcing Confidence Ahead Of Phase I Completion

SYDNEY, April 16, 2025 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) (together with its subsidiaries, "IREN"), today provided an update on its Bitcoin mining expansion.
"We're proud to have reached 40 EH/s, marking yet another significant step toward our 50 EH/s target," said Daniel Roberts, IREN Co-Founder and Co-CEO.
"The site team's rapid expansion of data center capacity at Childress coupled with our best-in-class fleet efficiency and low electricity costs has positioned IREN as one of the largest scale, lowest-cost producers of Bitcoin. We expect to maintain this momentum as we continue to scale mining capacity towards 50 EH/s over the coming months."
IREN has increased its installed self-mining capacity from 37 EH/s to 40 EH/s (15 J/TH efficiency), following the commissioning of additional mining hardware within its Childress Phase 4 (150MW) data centers.
The Company remains well-positioned to achieve 50 EH/s in H1 2025.

IREN

IREN Increases Installed Self-Mining Capacity From 37 EH/S To 40 EH/S; Co. Remains Well-Positioned To Achieve 50 EH/S In H1 2025

Chardan Capital analyst Keay Nakae initiates coverage on Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Buy rating and announces Price Target of $25.

Initiation

KRRO

Chardan Capital Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $25

Management

MDGL

Madrigal Pharmaceuticals' Founder Rebecca Taub, To Transition To Senior Scientific and Medical Advisor; David Soergel, Appointed Chief Medical Officer

NOTE

FiscalNote Holdings Announces The Latest Enhancement To Its Flagship Policy Monitoring Product, PolicyNote, With The Launch Of A Dedicated Tariff Tracker Available Within User Dashboards

K2 Cyber Announces Today Its Partnership With TransUnion For Commercial Cyber Services And Cyber Claims Management

IPOs

Press Releases

Waton Financial Limited Announces Pricing of Initial Public Offering

Waton Financial Limited Announces Closing of Initial Public Offering with Simultaneous Full Exercise of the Over-Allotment Option

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares

AMTD IDEA

BGC Group

Dominari Holdings

Evercore

Garden Stage

Lazard

Lion Group Holding Ltd. - American Depositary Share

Lion Group Holding

Moelis

MDB Capital Holdings, LLC - Class A common

MDB Capital Holdings

Magic Empire Global Limited - Class A Ordinary Shares

Magic Empire Glb

mF International Limited - Class A Ordinary Shares

mF International

Marex Group

Oppenheimer Holdings, Inc. Class A Common Stock (DE)

Oppenheimer Hldgs

Piper Sandler

PJT Partners

Plutus Financial Group Limited - Ordinary Shares

Plutus Financial Group

Perella Weinberg Partners - Class A Common Stock

Perella Weinberg

B. Riley Financial

Siebert Finl

StoneX Group

Solowin Holdings - Class A Ordinary Share

Solowin Holdings

UP Fintech Holding Limited - American Depositary Shares representing fifteen Class A Ordinary Shares

Comments

Waton Financial

ニュース

最新ニュース Waton Financial (NASDAQ:WTF) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル